Akero Therapeutics/$AKRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akero Therapeutics
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Ticker
$AKRO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
69
Website
AKRO Metrics
BasicAdvanced
$4B
-
-$3.74
-0.13
-
Price and volume
Market cap
$4B
Beta
-0.13
52-week high
$58.40
52-week low
$21.34
Average daily volume
1.3M
Financial strength
Current ratio
16.804
Quick ratio
16.171
Long term debt to equity
2.7
Total debt to equity
2.727
Interest coverage (TTM)
-63.41%
Profitability
EBITDA (TTM)
-306.33
Management effectiveness
Return on assets (TTM)
-18.52%
Return on equity (TTM)
-27.92%
Valuation
Price to book
3.71
Price to tangible book (TTM)
3.71
Price to free cash flow (TTM)
-13.79
Free cash flow yield (TTM)
-7.25%
Free cash flow per share (TTM)
-366.29%
Growth
Earnings per share change (TTM)
16.23%
3-year earnings per share growth (CAGR)
5.35%
What the Analysts think about AKRO
Analyst ratings (Buy, Hold, Sell) for Akero Therapeutics stock.
Bulls say / Bears say
Akero Therapeutics' Phase 2b SYMMETRY study demonstrated a statistically significant reversal of compensated cirrhosis after 96 weeks of treatment with efruxifermin (EFX), with 39% of patients in the 50mg EFX group showing ≥1 stage improvement in fibrosis. (stocktitan.net)
The company successfully closed a $402.5 million public offering in January 2025, bolstering its financial position and providing a runway into 2028. (nasdaq.com)
Analysts have raised their price targets for Akero, with Citi increasing its target to $80, citing the significance of the 96-week SYMMETRY data and the potential benefits of prolonged EFX treatment. (investing.com)
In October 2023, Akero's stock plummeted by over 60% following disappointing interim results from its Phase 2b study, where EFX did not meet the primary endpoint of improving liver fibrosis without worsening NASH. (fool.com)
The company's Chief Development Officer, Yale Catriona, sold approximately $2.73 million worth of stock in January 2025, which could be perceived negatively by investors. (investing.com)
Despite recent positive trial results, Akero faces competition from other companies developing NASH treatments, such as 89bio, which has reported fewer side effects and a more convenient dosing regimen for its drug candidate. (fool.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AKRO Financial Performance
Revenues and expenses
AKRO Earnings Performance
Company profitability
AKRO News
AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation
Accesswire·2 months ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect
Accesswire·2 months ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akero Therapeutics stock?
Akero Therapeutics (AKRO) has a market cap of $4B as of July 25, 2025.
What is the P/E ratio for Akero Therapeutics stock?
The price to earnings (P/E) ratio for Akero Therapeutics (AKRO) stock is 0 as of July 25, 2025.
Does Akero Therapeutics stock pay dividends?
No, Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next Akero Therapeutics dividend payment date?
Akero Therapeutics (AKRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Akero Therapeutics?
Akero Therapeutics (AKRO) has a beta rating of -0.13. This means that it has an inverse relation to market volatility.